8 Apr 2016 14:07
8 April 2016
Sphere Medical Holding plc
("Sphere Medical" or the "Company")
Directors' Shareholdings
Sphere Medical Holding plc (AIM: SPHR.L), a leading provider of innovative monitoring and diagnostic devices for the critical care setting, announces that on 8 April 2016 it was informed the following Directors' holdings of Ordinary Shares in the Company were transferred from nominee accounts with Peel Hunt LLP to nominee accounts managed by Panmure Gordon & Co.:
Name | Position | Number of Ordinary Shares in the Company transferred | Total number of Ordinary Shares held | Proportion of issued ordinary share capital |
Dr David Martyr | Non-Executive Chairman | 125,000 | 125,000 | 0.09% |
Dr Wolfgang Rencken | Chief Financial Officer | 449,470 | 449,470 | 0.32% |
Stephen Mahle | Non-Executive Director | 121,891 | 152,888 | 0.11% |
There is no change in the total beneficial holdings of these Directors in the Company.
- Ends -
For further information, please contact:
Sphere Medical Holding plc | Tel: +44 (0)1223 875 222 | |
Dr Wolfgang Rencken, Chief Executive Officer | ||
Richard Wright, Chief Financial Officer | ||
Panmure Gordon | Tel: +44 (0) 20 7886 2500 | |
Freddy Crossley (Corporate Finance) | ||
Duncan Monteith (Corporate Finance) | ||
Tom Salvesen (Corporate Broking) | ||
Consilium Strategic Communications | Tel: +44 (0) 20 3709 5700 | |
Mary-Jane Elliott | spheremedical@consilium-comms.com | |
Chris Gardner | ||
Ivar Milligan | ||
Hendrik Thys | ||
Notes for Editors
About Sphere Medical (AIM: SPHR.L)
Sphere Medical is a medical device company developing and commercialising a range of innovative monitoring and diagnostic devices designed to significantly improve patient care.
Sphere Medical's vision is to become a leading solution provider to the critical care market offering innovative, near real time, point of care diagnostic and monitoring products to enable closer control of therapeutic response and improve patient outcomes and reduce the overall cost of care.
The Company's strategy is focused on developing the Proxima (CE-marked device) platform for measuring blood gases, electrolytes and metabolites. The Company is already selling its Proxima 3 product directly to the critical care market, which includes the ICU and OR, with a dedicated field sales force in the UK, Germany, the Netherlands and Belgium. The Company also proposes to work with partners for the worldwide distribution of Proxima.
Proxima delivers near real time analysis of blood gases and electrolytes metabolites, at the patient's bedside. Proxima can be used on patients across a wide therapeutic range, enabling faster clinical decision making and improved patient outcomes, whilst potentially reducing costs for healthcare payers.
For further information, please visit www.spheremedical.com
Sphere Medical Holding (SPHR)